anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Guidelines recommend "rapid" and "urgent" reversal of anticoagulation for warfarin-associated intracranial hemorrhage (ICH) treatment; however, they do not specify goals for time-to-administration. There are limited studies evaluating time to reversal, or international normalized ratio (INR) correction, on hematoma expansion and outcomes in intervals of <4 h. The purpose of this study was to evaluate the association of 4-factor prothrombin concentrate (4F-PCC) time-to-administration on rates of achieving effective hemostasis, determined by hematoma expansion, for treatment of warfarin-associated ICH.
METHODS: This was a retrospective, observational, single center study performed at a large community teaching hospital. Patients were stratified into three groups based on time of CT diagnosis of ICH to administration of 4F-PCC: <45 min, 45-90 min, and >90 min. The primary outcome was rates of achieving effective hemostasis in each group defined as a ≤20% increase in hematoma volume as estimated by a radiologist.
RESULTS: A total of 227 patients were screened for inclusion with ultimately 39 being included. Baseline characteristics were similar between groups. The primary outcome was not significantly different among groups stratified by time to 4F-PCC administration of <45 min, 45-90 min, and >90 min (85.7% vs 73.3% vs 90%, p value 0.514). There was no difference among secondary outcomes between groups including in-hospital mortality, hospital length of stay (LOS), and intensive care unit LOS.
CONCLUSION: There was no association with time-to-administration of 4F-PCC on rates of hemostasis achievement, defined as hematoma expansion of ≤20%, identified in this study.
Lung ischemia-reperfusion (I/R) injury is the main risk factor for primary graft dysfunction and patient death after lung transplantation (LTx). It is widely accepted that the main pathological mechanism of lung I/R injury are calcium overload, oxygen free radical explosion and neutrophil-mediated damage, which leading to the lack of effective treatment options. The aim of this study was to further explore the mechanisms of lung I/R injury after LTx and to provide potential therapeutic strategies. Our bioinformatics analysis revealed that the neutrophil extracellular traps (NETs) formation was closely involved in lung I/R injury after LTx, which was accompanied by up-regulation of peptidylprolyl isomerase F (PPIF) and peptidyl arginine deiminase 4 (PADI4). We further established an orthotopic LTx mouse model to simulate lung I/R injury in vivo, and found that PPIF and PADI4 inhibitors effectively reduced neutrophil infiltration, NETs formation, inflammatory response, and lung I/R injury. In the neutrophil model induced by HL-60 cell line in vitro, we found that PPIF inhibitor cyclosporin A (Cys A) better alleviated calcium overload induced inflammatory response, reactive oxygen species content and NETs formation. Further study demonstrated that interfering with neutrophil PPIF protected mitochondrial function by alleviating store-operated calcium entry (SOCE) during calcium overload and played the above positive role. On this basis, we found that the reduction of calcium content in neutrophils was accompanied by the inhibition of calcineurin (CN) and nuclear factor of activated T cells (NFAT). In conclusion, our findings suggested that neutrophil PPIF could serve as a novel biomarker and potential therapeutic target of lung I/R injury after LTx, which provided new clues for its treatment by inhibiting calcium overload-induced NETs formation.
Post-extraction sockets will be treated with L-PRF plugs and membranes. First intervention: intraoral scan and intraoral scan and Cone Beam Computed Tomography in the treated zone. Clinicians will make a post-surgical control to evaluate how healing will be performed Four months after the first Intervention, participants will recall getting a second scan and Cone Beam Computed Tomography in the treated zone. Images will be used for implant treatment planification. Before implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses\* in the absence of disease progression or unacceptable toxicity. NOTE: \*Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain a novel and safe cosmetic composition. SOLUTION: The melanin formation inhibitor, active oxygen scavenger, lipoperoxide formation inhibitor, antiallergic agent, histamine liberation inhibitor, anticomplementary activator or cosmetic composition containing an extract from Rhei rhizoma is obtained. The cosmetic composition shows melanin formation inhibitory effect, active oxygen scavenging effect, lipoperoxide formation inhibitory effect, antiallergic effect, histamine liberation inhibitory effect or anticomplementary activation effect and exerts a stain or freckel reducing effect and a bleaching effect. Further, the skin inflammatory disease (e.g. rubor, edema, eczema or the like), skin roughness or dry skin is improved and the gloss and tension can be given to the skin. Furthermore, it can be utilized for other general foods and beverages.
The invention relates to an oral solution for conditioning male kidney yang deficiency. In modern society, the life and work pressure are enormous, male sexual dysfunction problems caused by kidney yang deficiency are increasing. At present, the market is western medicine oriented, although the effect is obvious, side effects also exist at the same time, and western medicines have a negative effect on the body after frequent taking. In order to solve the problems, the invention aims to prepare a traditional Chinese medicine for conditioning male kidney yang deficiency. The traditional Chinese medicine has the efficacy of regulating yin and yang, tonify liver and kidney, dredging collaterals and strengthening tendons, and nursing internal organs and qi and blood. According to the theory of traditional Chinese medicine, the oral solution provided by the invention is prepared from pure Chinese herbal medicines, and the specific traditional Chinese medicine formula comprises: cordyceps sinensis, Curculigo orchioides, Plantain seed, cistanche, rhizoma cibotii, semen allii tuberose, Chinese wolfberry, silkworm moth, Rubus idaeus, lotus stamen, herba epimedii, sika deer velvet antler, ginseng, hippocampus, and pipefish.
Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
BACKGROUND: Enterococcus avium (E. avium) is a Gram-positive nosocomial pathogen that is commonly isolated from the alimentary tract. The objective of this functional genomics study was to identify the resistant genes by analyzing the genome of E. avium IRMC1622a, a type of bacteria found in feces collected from a patient at a Saudi Arabian tertiary hospital.
METHODS: The bacterial strain IRMC1622a was identified by 16 S rRNA sequencing as Enterococcus sp. The resistance phenomics were performed using VITEK® 2, and morphological analysis was achieved using a scanning electron microscope (SEM). Finally, the whole bacterial genome of the bacterial strain IRMC1622a was subjected to sequencing during October 2023 using Oxford Nanopore long-read sequencing technology, and mining for resistant genes.
RESULTS: The results of antimicrobial resistant phenomics indicated that the IRMC1622a strain was sensitive to all tested antimicrobial agents except for erythromycin, and the same result was confirmed by genomic analysis in addition to other classes of antibiotics. SEM showed E. avium IRMC1622a is ovoid shape, in single cells (L 1.2797 ± 0.1490 µm), in pairs (L 1.7333 ± 0.1054 µm), and in chains (L 2.44033 ± 0.1978 µm). The E. avium IRMC1622a genome has 14 (in CARD) antimicrobial resistance genes that were identified with several mechanisms of antimicrobial resistance, such as the efflux pump and conferring antibiotic resistance. The present study revealed that the E. avium IRMC1622a genome contains a high number of genes associated with virulence factors, and 14 matched pathogenic protein families and predicted as human pathogen (probability score 0.855). We report two (ISEnfa4 and ISEfa5) mobile genetic elements for the first time in the E. avium genome.
CONCLUSIONS: The study concludes that E. avium IRMC1622a is susceptible to all tested antibacterials except erythromycin. The IRMC1622a has 14 genes encoding antimicrobial resistance mechanisms, including the efflux pump and conferring antibiotic resistance. This could indicate a potential rise in E. avium resistance in healthcare facilities. These observations may raise concerns regarding E. avium resistance in healthcare. We need more research to understand the pathophysiology of E. avium, which leads to hospital-acquired infections.
The present invention relates to a Chinese patent medicine composed of Chinese herbal medicines as raw materials, particularly to a medicine for treating apoplexy and a preparation method thereof. The main components comprise asarum heterotropoides fr. schmidt var. Mandshuricum maxim. Kitag, airpotato yam, combined spicebush root, green tangerine peel, largehead atractylodes rhizome, tabasheer, nutgrass galingale rhizome, stiff silkorm, olibanum, myrrh, cinnabar, fructus caryophylli, kudzuvine root, raw muskiness, pangolin scale, Chinese taxillus twig, plum blossom borneol, west cow-bezoar, safflower, dragon blood, ephedra, etc. The present invention has the characteristics of rapid therapeutic efficacy, no sequela and no toxicity or side effect.
Cellular senescence is widely acknowledged as having strong associations with cancer. However, the intricate relationships between cellular senescence-related (CSR) genes and cancer risk remain poorly explored, with insights on causality remaining elusive. In this study, Mendelian Randomization (MR) analyses were used to draw causal inferences from 866 CSR genes as exposures and summary statistics for 18 common cancers as outcomes. We focused on genetic variants affecting gene expression, DNA methylation, and protein expression quantitative trait loci (cis-eQTL, cis-mQTL, and cis-pQTL, respectively), which were strongly linked to CSR genes alterations. Variants were selected as instrumental variables (IVs) and analyzed for causality with cancer using both summary-data-based MR (SMR) and two-sample MR (TSMR) approaches. Bayesian colocalization was used to unravel potential regulatory mechanisms underpinning risk variants in cancer, and further validate the robustness of MR results. We identified five CSR genes (CNOT6, DNMT3B, MAP2K1, TBPL1, and SREBF1), 18 DNA methylation genes, and LAYN protein expression which were all causally associated with different cancer types. Beyond causality, a comprehensive analysis of gene function, pathways, and druggability values was also conducted. These findings provide a robust foundation for unravelling CSR genes molecular mechanisms and promoting clinical drug development for cancer.
Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.
As with other 5-HT1 agonists, significant elevations in systemic blood pressure have been reported on rare occasions with ZOMIG Tablet use, in patients with and without a history of hypertension; very rarely these increases in blood pressure have been associated with significant clinical events. Zolmitriptan is contraindicated in patients with uncontrolled hypertension. In volunteers, an increase of 1 and 5 mm Hg in the systolic and diastolic blood pressure, respectively, was seen at 5 mg. In the headache trials, vital signs were measured only in the small inpatient study and no effect on blood pressure was seen. In a study of patients with moderate to severe liver disease, 7 of 27 experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a dose of 10 mg of zolmitriptan (see CONTRAINDICATIONS).

An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5-HT1 agonist in a study evaluating subjects undergoing cardiac catheterization.
To minimize the possibility of gastrointestinal irritation associated with the oral ingestion of concentrated potassium salt preparations, patients should be directed to dissolve each dose completely in the stated amount of water.

Each dose should be taken immediately after a meal or with food. Patients should avoid low-salt foods and salt substitutes, unless approved by physician. The patient should be cautioned to comply strictly with the regimen, particularly when taking diuretics or digitalis, to visit the physician regularly and to report at once any unusual symptoms (e.g. blackish stools, a sign of gastrointestinal bleeding). As with any other medicine, the patient should be counseled on this background information and advised to report to the physician any changes in routine (e.g. starting a fitness program). Proper storage and handling of the product is important. Tablets should not be removed from foil pouch until shortly before use.
There is a 6-month intervention period immediately following recruitment. Participants enrolled in the intervention will complete 5 educational sessions and attend 2 one-on-one virtual meetings.
The application provides a hair growth and hair loss prevention application of kaempferia galanga essential oil. Use of kaempferia galanga essential oil in the preparation of a composition for dermal application. The skin application composition is a hair growth and hair loss prevention medicine. The skin application composition is for promoting hair growth. The promoting hair growth includes promoting proliferation of human dermal papilla cells, and/or regulating levels of hair growth-related cell growth factors, and/or improving hair growth cycle. The preparation method of the kaempferia galanga essential oil comprises a steam distillation method or a supercritical carbon dioxide extraction method. The total content of cinnamate, olefin compounds, borneol and sitosterol in the rhizoma kaempferiae essential oil accounts for more than 90% of the total mass of the rhizoma kaempferiae essential oil. The skin application composition is applied to a pharmaceutical preparation or a daily chemical product. The kaempferia galanga essential oil is added into the pharmaceutical preparation or the daily chemical product in a mass percentage of 0.1% -20%.
Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
The invention discloses a preparation method of a traditional Chinese medicine Rosa maximowicziana Regel solution for improving memory. The traditional Chinese medicine Rosa maximowicziana Regel solution comprises, by dry weight, 6-12 parts of Rosa maximowicziana Regel, 10-15 parts of rhizoma polygonati, 6-10 parts of fructu broussonetiae, 6-15 parts of luffa leaves, 6-15 parts of spina date seeds, 5-15 parts of red sage root, 10-15 parts of radix astragali and 6-12 parts of radix angelicae sinensis. An ethanol solution for extraction has a concentration of 4-15% (by volume), first extraction time of the Rosa maximowicziana Regel solution is in a range of 10-15 days and second extraction time of the Rosa maximowicziana Regel solution is in a range of 3-7 days. The preparation method is simple and safe and has a low cost. The traditional Chinese medicine Rosa maximowicziana Regel solution has no toxic or side effect. The traditional Chinese medicine Rosa maximowicziana Regel solution realizes treatment on both symptoms and root causes of chronic diseases formed in a long time and has effects of reducing blood viscosity, cleaning blood and cholesterol on the blood vessel wall, softening vessels, benefiting qi for activating blood circulation and satisfying body organs nutrient and oxygen demands. The traditional Chinese medicine rhizoma gastrodiae solution treats multiple symptoms through one formula, produces synergism and thoroughly improves memory.
PROBLEM TO BE SOLVED: To obtain an antithrombotic drug by containing an antihuman von Willebrand factor monoclonal antibody and antifibronectin antibody. SOLUTION: This antithrombotic drug contains an antihuman von Willebrand factor monoclonal antibody, antifibronectin antibody and optionally laminin- derived peptide. The antihuman von Willebrand factor monoclonal antibody has the following properties; (a) it is reactive with a human von Willebrand factor, and (b) it inhibits human platelet agglutination elicited by ristocetin, bottrocetin, or high shear stress. These properties make the drug highly effective in treatment of human thromboses, e.g. ischemic heart diseases or cerebral vascular accidents. Its daily dosage is 0.001mg to 1g per adult.
The present invention relates to a preparation method of a functionalized macromolecular microsphere with a hydrophilic core/a hydrophilic or hydrophobic shell, corresponding microsphere products and the application thereof, which relates to the technical filed of the preparation of functionalized macromolecular materials, medicine coating materials and release control materials. The present invention solves the technical problem of using functionalized macromolecular materials to coat medicine and control the release of medicine. Firstly, a macromolecular crosslinking microsphere with a hydrophilic core/a hydrophobic shell is synthesized by the grafting and crosslinking reaction of a macromonomer of PBMA (poly butyl methacrylate), Am (acrylamide) and a crosslinking agent; then, the macromolecular crosslinking microsphere with a hydrophilic core/a hydrophobic shell is dried at constant temperature and is hydrolyzed in acidic solution so as to obtain a macromolecular crosslinking microsphere with a hydrophilic core/a hydrophilic shell. The macromolecular crosslinking microsphere with a hydrophilic core/a hydrophobic shell can be used as an impact resistant and toughening modifying agent. The macromolecular crosslinking microsphere with a hydrophilic core/a hydrophilic shell has pH value sensibility and achieves the effect of medicine coating and release control. The preparation method is an initiative technological line for synthesizing functionalized macromolecular microspheres.
The study included fifty-six patients with bilateral concha bullosa who were undergoing primary ESS for refractory chronic sinusitis. They were divided into two equal groups randomly. One group had the submucosal conchoplasty technique, and the other group had the lateral lamellectomy technique. The study compared the intraoperative findings including the time required for each technique and the amount of intraoperative bleeding. Furthermore, it compared the postoperative endoscopic outcome of the middle meatus and middle turbinate stability using the LKES and the POSE score. Also, the postoperative olfaction outcome was assessed.
Nivolumab is a programmed death-1 receptor blocker within the family of medications called immune checkpoint inhibitors (ICIs). Although generally well tolerated, cases of immune-related adverse events (irAEs) have been reported. We present a case of a man being treated with nivolumab for renal cell carcinoma who presented to the emergency department with problems of headache, fever and disorientation. After extensive evaluation, a diagnosis of immunotherapy-induced aseptic meningitis was considered more probable than infectious. Due to stable clinical status, no treatment was initiated, and the patient's condition improved spontaneously. The patient was discharged home. To date, only a handful of prior cases of nivolumab-induced meningitis have been reported. Our case demonstrates that irAEs can occur years after the initiation of ICIs. This was a milder presentation of a neurological irAE that resolved spontaneously with watchful waiting, showing that irAEs are likely an evolving spectrum of disease for which clinicians should be aware.
The present invention relates to a medical liver soothing enzyme for treating hepatitis. Refined snake venom is obtained from snake venom of multiple snakes by the steps of chromatographic separation of two times, saturated ammonium sulfate sedimentation, centrifugation, dialysis, refrigeration and dryness; then, the medical liver soothing enzyme is formed by preparing, filtering, sterilizing, pouring and sealing the refined snake venom. Each ampoule is one milliliter and comprises 0.25 to 1.00 u/ml of arginine ester enzyme energy unit, 0.001 to 0.1 u/ml of liver cell growth factors, previous VC and low-molecule dextran. Basic researches prove that the liver soothing enzyme has protective function of endotoxin putrescence and has the functions of resisting fibers, dissolving thrombus, reducing blood grease and improving microcirculation. The present invention especially comprises liver cell growth factors which can enhance the growth activity of liver cells. The medical liver soothing enzyme is applied to clinic for thousands of cases; the total effective rate on viral hepatitis reaches 85.0 to 91.7%.
OBJECTIVES: I. Determine the response rates in patients with previously untreated aggressive non-Hodgkin's lymphoma treated with doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone (EPOCH). II. Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.